Needham Downgrades Sage Therapeutics to Hold
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia has downgraded Sage Therapeutics from Buy to Hold.
August 08, 2023 | 10:22 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics has been downgraded from Buy to Hold by Needham analyst Ami Fadia.
The downgrade from Buy to Hold by a Needham analyst indicates a less optimistic outlook for the company's stock. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100